Fengze Wang
Beijing, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Neutralizing antibodies against Chikungunya virus and structural elucidation of their mechanism of action.
Journal: Nature communications
Published: September 05, 2024
A combination vaccine against SARS-CoV-2 and H1N1 influenza based on receptor binding domain trimerized by six-helix bundle fusion core.
Journal: EBioMedicine
Published: June 27, 2022
Etesevimab in combination with JS026 neutralizing SARS-CoV-2 and its variants.
Journal: Emerging microbes & infections
Published: January 21, 2022
A non-ACE2-blocking neutralizing antibody against Omicron-included SARS-CoV-2 variants.
Journal: Signal transduction and targeted therapy
Published: December 29, 2021
Distinct BCR repertoires elicited by SARS-CoV-2 RBD and S vaccinations in mice.
Journal: Cell discovery
Published: June 10, 2021
Publisher Correction: A single-dose mRNA vaccine provides a long-term protection for hACE2 transgenic mice from SARS-CoV-2.
Journal: Nature communications
Published: April 16, 2021
A broadly neutralizing humanized ACE2-targeting antibody against SARS-CoV-2 variants.
Journal: Nature communications
Published: March 22, 2021
Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials.
Journal: The Lancet. Infectious diseases
Published: January 12, 2021
A single-dose mRNA vaccine provides a long-term protection for hACE2 transgenic mice from SARS-CoV-2.
Journal: Nature communications
Published: September 25, 2020
Showing 1-9 of 9
Last Updated: 09/26/2026